NCKAF yields 4.72% · JNJ yields 2.13%● Live data
📍 JNJ pulled ahead of the other in Year 8
Combined, NCKAF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of NCKAF + JNJ for your $10,000?
Nickel Asia Corporation engages in the mining and exploration of nickel saprolite, limonite ore, limestone, and quarry materials in the Philippines. It operates through Mining, Services, and Power segments. The company operates four mines, including Rio Tuba, Taganito, Cagdianao, and Taganaan mines located in the Philippines. It also has other properties in various stages of exploration for nickel, as well as for gold and copper. The company exports its saprolite and limonite ores for use in the production of ferronickel and nickel pig iron that is used to produce stainless steel, as well as to produce pig iron used for carbon steel. In addition, it is involved in the chartering out of landing craft transport, as well as the provision of marine services; and leasing of aircraft. Further, the company engages in the exploration, exploitation, and mining of metallic and non-metallic minerals, including iron, cobalt, chromite, and other associated mineral deposits; general engineering construction activities; and handling of materials in connection with construction or manufacturing, warehousing, distribution or disposal activities, and other related activities. Additionally, it is involved in renewable energy generation; and trading, manufacturing, real estate, and agribusiness activities. Nickel Asia Corporation was founded in 1977 and is headquartered in Taguig City, the Philippines.
Full NCKAF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.